ONCOLYTICS BIOTECH INC

Oncolytics CEO’s July 20 insider trades reveal a balanced strategy, selling shares while buying back at low prices amid FDA fast‑track approval for pelareorep in anal‑cancer patients, indicating long‑term confidence in the company’s oncolytic viroth…

Oncolytics CEO’s fresh ADS purchase signals confidence amid falling stock, hinting at future growth from REOLYSIN and AI‑powered oncology deals.

Oncolytics insider sale signals mixed confidence: CEO’s Rule 10b‑5‑1 trades reveal long‑term strategy amid FDA review and REO 033 milestones. Investors must weigh short‑term volatility against future upside.

Oncolytics insider sales show strategic rebalancing amid a bullish market, patent extensions, and upcoming regulatory milestones—key insight for investors.

Oncolytics insider sales are routine RSU vesting moves that won’t hurt the stock—yet the firm’s 37.9% revenue growth and REOLYSIN pipeline keep investors optimistic.

Oncolytics insider sale: Yi Qingqing liquidates her 235 ADSs amid growing executive trades and a fast‑track REOLYSIN pipeline—what this means for investor confidence.

Oncolytics insider buys signal confidence as pelareorep shows promising Phase IIb data, balanced by liquidity moves and a 12‑month IND extension.

Oncolytics insider trades reveal disciplined Rule 10b5‑1 strategy, confidence in its REOLYSIN platform and a focus on liquidity as the oncology pipeline expands.

Insider buy by Oncolytics’ SVP signals confidence in its Reovirus‑based cancer therapy, REOLYSIN, and its clinical‑trial progress toward future approvals.

Oncolytics Biotech insider buying signals executive confidence—discover how strategic purchases of ADS by senior VP Lee Chan Henry could hint at future stock upside and key milestones.